Literature DB >> 1417105

Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease.

D M Friedman1, H J Mitnick, D Danilowicz.   

Abstract

This paper describes the case of an 11 year old girl who presented with mixed connective tissue disease which was complicated by the development of pulmonary hypertension. This case is unique with respect to the young age of onset, the serial non-invasive method used to follow the disease process, and the favourable response to treatment with vasodilator and anti-inflammatory drugs.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1417105      PMCID： PMC1004814          DOI： 10.1136/ard.51.8.1001

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  17 in total

1.  Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?

Authors:  A Bush; C Busst; K Booth; W B Knight; E A Shinebourne
Journal:  Circulation       Date:  1986-07       Impact factor: 29.690

2.  An echocardiographic index for separation of right ventricular volume and pressure overload.

Authors:  T Ryan; O Petrovic; J C Dillon; H Feigenbaum; M J Conley; W F Armstrong
Journal:  J Am Coll Cardiol       Date:  1985-04       Impact factor: 24.094

3.  Frequency of mitral valve prolapse in systemic lupus erythematosus, progressive systemic sclerosis and mixed connective tissue disease.

Authors:  S M Comens; M A Alpert; G C Sharp; T A Pressly; D L Kelly; S E Hazelwood; V Mukerji
Journal:  Am J Cardiol       Date:  1989-02-01       Impact factor: 2.778

4.  Mixed connective tissue disease in childhood. A clinical and serologic survey.

Authors:  B H Singsen; B H Bernstein; H K Kornreich; K K King; V Hanson; E M Tan
Journal:  J Pediatr       Date:  1977-06       Impact factor: 4.406

5.  The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.

Authors:  S Rich; B H Brundage; P S Levy
Journal:  Circulation       Date:  1985-06       Impact factor: 29.690

6.  Fatal pulmonary hypertension and resolving immune-complex glomerulonephritis in mixed connective tissue disease. A case report and review of the literature.

Authors:  M B Jones; R K Osterholm; R B Wilson; F H Martin; J R Commers; J D Bachmayer
Journal:  Am J Med       Date:  1978-11       Impact factor: 4.965

7.  Interventricular septal configuration as a predictor of right ventricular systolic hypertension in children: a cross-sectional echocardiographic study.

Authors:  M E King; H Braun; A Goldblatt; R Liberthson; A E Weyman
Journal:  Circulation       Date:  1983-07       Impact factor: 29.690

8.  Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy.

Authors:  M Cohen; W D Edwards; V Fuster
Journal:  J Am Coll Cardiol       Date:  1986-01       Impact factor: 24.094

9.  Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique.

Authors:  A Kitabatake; M Inoue; M Asao; T Masuyama; J Tanouchi; T Morita; M Mishima; M Uematsu; T Shimazu; M Hori; H Abe
Journal:  Circulation       Date:  1983-08       Impact factor: 29.690

10.  Antinuclear antibodies in primary pulmonary hypertension.

Authors:  S Rich; K Kieras; K Hart; B M Groves; J D Stobo; B H Brundage
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094
View more
  1 in total

1.  High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.

Authors:  Eileen M Bauer; Richard Shapiro; Han Zheng; Ferhaan Ahmad; David Ishizawar; Suzy A Comhair; Serpil C Erzurum; Timothy R Billiar; Philip M Bauer
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.